not that it matters ......... the correct term is Emerging...

First 65 Last

Share
Profile

Follow
1stPrize

2,046 Posts.

551

27/08/23

17:02

Post #: 69572378
Share

Originally posted by moguns: ↑

Here's an explanation for you.

There are macro conditions impacting speculative stocks across the board. Particularly biotechs. When people's investments are at risk, they will sell. Maybe because they need the funds, maybe because they believe they can re-enter once the dust settles. Whatever the reason, keeping your capital tied up in a spec stock is risky. More risk = less buying. I'm sure you understand this concept. If you disagree with the above, feel free to provide evidence to the contrary.

Then consider the company's timelines which are known to the market. Following previous 42x results there is a 2 year wait until the next phase. Again, why keep your money invested if you don't need to. Why invest in IHL today if I believe I can buy for 6c in a few months time. It's a trend that likely won't be broken without material updates re: revenue. That doesn't mean those updates won't happen, but they're unlikely to happen in the immediate future. So, again... we wait.

Psychedelics are the outlier. It's possible we might see revenue earlier than expected thanks to the CR at 20c. But the SP won't react because the market is unproven. I guess that's the epitomy of risk / reward. The company is taking a risk opening the first dedicated psychedelic clinic in Australia. The market is waiting to see if this is a genuine industry or just a flash in the pan.

There are many reasons why the sp is where it is and they have nothing to do with the trial results. I would flip the question on to you. If the 42x trial results were so bad, can you explain why?

Expand

not that it matters ......... the correct term is Emerging Growth Company..... that is the box that was ticked for the nasdaq application. means they have limits on annual revenue (not a problem and was not gunna be really for a while ... about 1 or 2 billion or something). they did have that $2M odd revenue till recently though.......

one downside to that is they do not disclose director revenues/payments if US domiciled.... nor can shareholders have any vote on that... i think.... peeps here would know i spose..... not that it matters.

Last edited by 1stPrize: 27/08/23

IHL Price at posting: 8.8¢ Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Making money: How many microcaps should be in an investor's portfolio?

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too